Stamler was one of the authors of this paper. Now in this news...

Stamler was one of the authors of this paper. Now in this news report to shareowners, he has more possibilities to tell proudly what facts in his opinion are the most valuable for the shareowners, in comparison to the critical scientific audience.

-"ATH434 preserves neurons while reducing α-synuclein in areas of pathology is exactly what we were hoping to see".

-"we believe that ATH434 can treat the underlying cause of this devastating disease which has no approved therapy".

- " treatment with ATH434 was neuroprotective and improved motor function, ........as well as animal models of Parkinson’s
Disease".(a reference to earlier Finkelstein paper in Parkinson's disease animal models, PD is the main indication for ATH434 in the future)

- ", ATH434 reduced both the aggregated form of α-synuclein and the so-called toxic oligomeric form, which is thought to underlie the spreading of the disease to other neurons".

-"ATH434 significantly reduced brain iron in areas of pathology, consistent with its mechanism of action". ( most likely there will be a mitochondrion level paper later explaining more exactly the mechanism of action, maybe Stamler already knows this)

- "the first time that ATH434 preserved neurons in a region of the brain called the striatum, that is known to be affected in patients with
MSA". ( Striatum is affected also in PD, not only in MSA, but this is a very important issue, IMO).

- "ATH434 improved performance on diverse motor tests".